Livzon Pharma's 3-Month Leuprorelin Acetate Microspheres 11.25mg Wins Supplementary Drug Application Approval

Stock News
09/29

Livzon Pharma (01513) has announced that its controlling subsidiary, Shanghai Livzon Pharmaceutical Co., Ltd. (Shanghai Livzon), recently received the "Drug Supplementary Application Approval Notice" (Certificate No.: 2026B06648) issued by the National Medical Products Administration, granting market approval for the leuprorelin acetate microspheres for injection 11.25mg (3-month formulation) produced by Shanghai Livzon.

The leuprorelin acetate microspheres for injection is a Class B product listed in the "National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug Catalog." The indications for the 3-month formulation include: (1) premenopausal breast cancer; (2) prostate cancer; (3) central precocious puberty.

The leuprorelin acetate microspheres for injection (3-month formulation) is administered via subcutaneous injection once every 12 weeks, distinguishing it from the already marketed 3.75mg 1-month formulation. The 3-month formulation differs in formulation process, quality standards, dosage and administration, and indications. The 3-month formulation uses a completely different core excipient, poly-DL-lactide, offering the advantages of longer duration of action and fewer administrations. After injection, it maintains stable blood drug concentrations for 12 weeks, with more stable release behavior, significantly reducing the blood drug concentration fluctuations associated with repeated administration of the 1-month formulation. This alleviates patient suffering and medication burden while improving drug tolerability and accessibility.

Poly-DL-lactide is a high-molecular-weight excipient independently developed by Shanghai Livzon and serves as the core excipient controlling microsphere release. Following the successful associated review this time, the registration status of this excipient has been changed to "A." After PLGA7525, poly-DL-lactide is the company's second approved polymer, further enhancing the company's competitiveness in microsphere technology research and development.

As of the disclosure date of this announcement, the cumulative direct R&D expenses invested in leuprorelin acetate microspheres for injection (3-month formulation) amount to approximately RMB 94.0548 million.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10